Lenmeldy (atidarsagene autotemcel) - Medicare Advantage

This policy addresses coverage of Lenmeldy (atidarsagene autotemcel), a gene therapy for metachromatic leukodystrophy (MLD) and related leukodystrophies. It references patients with ARSA‑mutation MLD across late‑infantile, juvenile, and adult‑onset presentations but the provided excerpt contains no explicit covered indications, age/frequency limits, prior‑authorization or exclusion criteria, so coverage is subject to the member’s plan, medical director review, and periodic policy updates (no CMS NCDs/LCDs specified).

"Individual 18 years of age or older; OR"

Sign up to see full coverage criteria, indications, and limitations.